Brian Druker, MD

Brian J. Druker, MD, is a hematologist-oncologist specializing in hematologic malignancies, particularly chronic myeloid leukemia (CML) and chronic neutrophilic leukemia. He serves adult patients with these life-threatening leukemias, including those with treatment-resistant cases, at the OHSU Knight Cancer Institute in Portland, Oregon. Druker pioneered precision medicine through his development of imatinib (Gleevec), the first targeted therapy that inhibits the BCR-ABL tyrosine kinase driving